Norepinephrine Weaning Guided by the Hypotension Prediction Index in Vasoplegic Shock After Cardiac Surgery

Study Overview
=================
Brief Summary
-----------------
In postoperative cardiac surgery under extracorporeal circulation, the patient may develop a vasoplegic syndrome, characterized by arterial hypotension (mean arterial pressure (MAP) < 65 mmHg); a decrease in vascular resistance and a cardiac output that may be normal or increased, and increased postoperative mortality/ International recommendations recommend the prescription of noradrenaline as a first-line treatment to reduce morbidity and mortality. However, excess norepinephrine or duration of exposure is also deleterious. The Acumen IQ device (Edwards Lifesciences) allows the calculation of a predictive index of arterial hypotension episodes (predictive hypotension index, HPI). HPI could improve norepinephrine weaning by preventing episodes of arterial hypotension or detecting preload dependence, thus avoiding the transient increase in norepinephrine during hypotension. This is a single-center, prospective, open-label, randomized, controlled, 2-group, parallel, intention-to-treat study. The aim was to evaluate the superiority of a new decision algorithm, based on the HPI delivered by the Acumen IQ device, to reduce the duration of norepinephrine administration in post-cardiac surgery vasoplegic shock. The duration of the interventional protocol is 72 hours. To evaluate the clinical impact of the protocol, the time of the study will be 30 days. Several follow-up visits will be performed (end-of-protocol day, discharge day, and at D30 of inclusion) to collect clinical, biological, and HPI monitoring data.

Official Title
-----------------
Norepinephrine Weaning Guided by the Hypotension Prediction Index in Vasoplegic Shock After Cardiac Surgery

Conditions
-----------------
Vasoplegia, Shock, Norepinephrine, Surgery

Intervention / Treatment
-----------------
* Drug: norepinephrine weaning protocol
* Drug: norepinephrine weaning protocol and guided by the HPI


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age > 18 years The patient was hospitalized in the cardiothoracic-vascular and respiratory intensive care unit of Amiens-Picardy University Hospital. Patient scheduled for on-pomp cardiac surgery [coronary artery bypass grafting, valve replacement, ascending aorta replacement, or combined surgery (valve and bypass grafting)]. Introduction of norepinephrine post-surgery for the treatment of vasoplegic syndrome. On-pomp cardiac surgery in less than 48 hours. Hemodynamically stable patient with MAP > 65 mmHg for more than 4 hours on noradrenaline Monitoring of MAP with a radial or femoral arterial catheter Social security beneficiary Signature of the consent to participate in the study by the patient, preoperatively Exclusion Criteria: Permanent arrhythmia (atrial fibrillation, flutter, or frequent atrial extrasystoles). Treatment with dobutamine, epinephrine, or vasopressin analog Patients with preoperative chronic end-stage renal failure require postoperative extra-renal purification. Pregnant woman The patient is dependent on an internal or external pacemaker. Hypothermia < 36°. Patient under mechanical circulatory assistance after cardiac surgery. Hemorrhagic shock Patient under guardianship or curators

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Standard care arm<br>MAP-based (MAP > 65 mmHg) norepinephrine weaning protocol | Drug: norepinephrine weaning protocol<br>* MAP-based (MAP > 65 mmHg) norepinephrine weaning protocol<br>|
| Experimental: Experimental arm (HPI-guided)<br>MAP-based (MAP > 65 mmHg) norepinephrine weaning protocol and guided by the HPI (HPI<80) delivered by the Acumen IQ medical device. | Drug: norepinephrine weaning protocol and guided by the HPI<br>* MAP-based (MAP > 65 mmHg) norepinephrine weaning protocol and guided by the HPI (HPI<80) delivered by the Acumen IQ medical device.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| variation of the duration of norepinephrine administration between both groups |  | 72 hours | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of norepinephrine protocol weaning failures | Number of norepinephrine protocol weaning failures, defined as persistent norepinephrine delivery 72 hours after the start of inclusion | 2 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
vasoplegia, shock, hypotension prediction index, Acumen, CABG, norepinephrine, surgery